Skip to Content

Vitrasert Implant

Active Substance: ganciclovir
Common Name: ganciclovir
ATC Code: J05AB06
Marketing Authorisation Holder: Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH..
Active Substance: ganciclovir
Status: Withdrawn
Authorisation Date: 1997-03-18
Therapeutic Area: Cytomegalovirus Retinitis HIV Infections
Pharmacotherapeutic Group: Antivirals for systemic use

Therapeutic Indication

The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).

The marketing authorisation for Vitrasert Implant has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.